Allergy Therapeutics plc (AGY) Insider Acquires £12,750 in Stock
Allergy Therapeutics plc (LON:AGY) insider Tunde Otulana bought 25,000 shares of the business’s stock in a transaction dated Wednesday, October 11th. The shares were bought at an average cost of GBX 51 ($0.67) per share, for a total transaction of £12,750 ($16,763.08).
Allergy Therapeutics plc (AGY) traded down 0.66% during trading on Thursday, hitting GBX 37.75. The stock had a trading volume of 101,757 shares. Allergy Therapeutics plc has a 12 month low of GBX 19.50 and a 12 month high of GBX 39.50. The company’s market cap is GBX 224.28 million. The company’s 50 day moving average is GBX 31.85 and its 200-day moving average is GBX 28.57.
Several research firms have recently weighed in on AGY. FinnCap boosted their target price on Allergy Therapeutics plc from GBX 43 ($0.57) to GBX 46 ($0.60) and gave the company a “buy” rating in a research report on Tuesday, July 18th. Panmure Gordon reissued a “buy” rating on shares of Allergy Therapeutics plc in a research report on Thursday, September 28th. Finally, Numis Securities Ltd reissued a “buy” rating and set a GBX 45 ($0.59) target price on shares of Allergy Therapeutics plc in a research report on Thursday, September 28th.
Allergy Therapeutics plc Company Profile
Allergy Therapeutics Plc is a pharmaceutical company. The Company focuses on the treatment and prevention of allergy with aluminum-free products. The Company’s segments are Central Europe, which includes segments, such as Germany, Australia, Switzerland and the Netherlands; Southern Europe, which includes Italy and Spain; the United Kingdom, and Rest of World.
Receive News & Ratings for Allergy Therapeutics plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergy Therapeutics plc and related companies with Analyst Ratings Network's FREE daily email newsletter.